金吾财讯 | 礼来(LLY)股价走高，截止发稿，涨16.27%，报854.457美元。与此同时，诺和诺德(NVO)股价走低，跌8.45%，报57.56美元。
消息面上，公司宣布III期ACHIEVE-1研究取得积极结果，该研究评估了orforglipron与安慰剂相比在饮食和运动单独控制不佳的2型糖尿病成人中的安全性和疗效。Orforglipron是首个成功完成III期研究的口服小分子胰高血糖素样肽-1(GLP-1)受体激动剂，服用时无需食物和水限制。
Orforglipron在后期试验中，最高剂量下可使 2 型糖尿病患者体重减轻16.0 磅（7.9%），并降低血糖。礼来公司表示，研究结束时患者尚未达到体重平台期，这表明患者减重幅度可能更大。
投资者和分析师此前预计，该药物的疗效至少会与诺和诺德公司旗下的重磅糖尿病药物奥泽匹克（Ozempic）一样好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.